Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL21819626 | 0.91 | CNR1 (0.42) | CNR1MAOBSLC6A3KCNH2TAAR1 | |
| SCHEMBL21882037 | 0.82 | EGLN1 (0.42) | KCNH2 | |
| SCHEMBL21882044 | 0.81 | KMT2A (0.49) | CNR1KCNH2CNR2 | |
| SCHEMBL21882368 | 0.80 | MAOB (0.47) | CNR1MAOBCNR2SMN1; SMN2 | |
| SCHEMBL21882371 | 0.79 | ATF4 (0.53) | CNR1KCNH2CNR2 | |
| SCHEMBL21882079 | 0.78 | SMN1; SMN2 (0.67) | SMN1; SMN2 | |
| SCHEMBL25411521 | 0.78 | L3MBTL1 (0.60) | CNR1SMN1; SMN2 | |
| SCHEMBL21819339 | 0.77 | ATF4 (0.47) | CNR1MAOB | |
| Trifluoroacetic Acid SCHEMBL21819534 | 0.77 | KMT2A (0.45) | CNR1KCNH2CNR2SMN1; SMN2 | |
| SCHEMBL28584086 | 0.75 | CNR1 (0.42) | CNR1MAOBCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166942-B2 | Inhibitors of integrated stress response pathway | Praxis Biotech LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166942-B2 | Inhibitors of integrated stress response pathway | ATF4, DDIT3, ATF1 | CNR1 2950/4885MAOB 2567/4885SLC6A3 1525/4885 |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | CNR1 2950/4885MAOB 2567/4885SLC6A3 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.